Neovasc Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Fredericus A. Colen
- Full Time Employees
- 49
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 13562 Maycrest Way Richmond BC Canada V6V 2J7
- IPO Date
- May 23, 2001
- CIK
- 0001399708
- Website
- neovasc.com
- Similar Companies
- Business
- Neovasc Inc is a specialty medical device company focused on developing, manufacturing, and marketing products for the cardiovascular marketplace. Its core products include the Neovasc Reducer System, a first-of-its-kind implant designed for the treatment of refractory angina, which is currently commercially available in Europe and under clinical investigation in the United States and Canada. The Reducer is a minimally invasive transvenous implant that improves myocardial blood flow to alleviate chest pain symptoms in patients who do not respond to conventional therapies. In addition to the Reducer, Neovasc offers the Tiara device for the transcatheter treatment of mitral valve disease, which remains under clinical investigation in North America and Europe, as well as a line of advanced biological tissue products used as key components in third-party cardiovascular medical devices. Founded in 1999 and headquartered in Richmond, British Columbia, Canada, Neovasc operates primarily in North America and Europe. Its products serve patients with complex cardiovascular conditions such as obstructive coronary disease and refractory angina. The company generates revenue mainly from the Reducer, which received a breakthrough device designation from the U.S. FDA and is currently being studied in the COSIRA-II pivotal clinical trial enrolling patients across multiple sites in the U.S. and Canada. Neovasc has also secured outpatient reimbursement coding in the U.S. for the Reducer implant procedure, supporting wider adoption in hospital settings. A significant recent development for Neovasc is its acquisition by Shockwave Medical Inc., completed in early 2023 following shareholder approval. The transaction valued Neovasc at approximately $100 million, including upfront cash payments and potential deferred milestone payments tied to FDA regulatory achievements for the Reducer device. This acquisition aligns with Shockwave Medical’s strategy to expand its portfolio of innovative cardiovascular technologies and enhances commercialization capabilities across global markets. Neovasc continues to focus on advancing its lead products, with the Tiara clinical program currently paused but patient follow-up ongoing. Overall, Neovasc operates in the cardiovascular medical devices industry, targeting hospitals and healthcare providers treating complex cardiovascular diseases. Its recent integration into Shockwave Medical marks a strategic expansion aimed at accelerating product development, regulatory approvals, and market penetration of its minimally invasive cardiovascular therapies. The company’s technology portfolio centers on innovative implantable devices designed to address unmet clinical needs in refractory angina and valvular heart disease.
Shockwave Medical, Inc. Completes Acquisition of Neovasc
Shockwave Medical Completes Acquisition of Neovasc
Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update
Neovasc Shareholders Approve Acquisition by Shockwave Medical
A Bull Market Is Coming: 1 Outstanding Growth Stock Down 36% to Buy and Hold
Neovasc Announces German Reimbursement Renewal
Mergers and Acquisitions in 2023 Off To A Strong Start
Shockwave Medical To Buy Neovasc: Details (NVCN)
Shockwave Medical to Acquire Neovasc
Neovasc (NVCN) is on the Move, Here's Why the Trend Could be Sustainable
Recent Price Trend in Neovasc (NVCN) is Your Friend, Here's Why
Neovasc Announces Progress on COSIRA-II Clinical Trial
Neovasc Comments on European Heart Journal Publication
Neovasc (NVCN) Reports Q3 Loss, Misses Revenue Estimates
Neovasc Inc. (NVCN) Q3 2022 Earnings Call Transcript
Neovasc Announces Third Quarter Financial Results and Provides Corporate Update
Neovasc Reducer Obtains U.S. Outpatient Reimbursement
Neovasc Provides Corporate Update Following Clinical Data Release
Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit
Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina